Immune modulation in heart failure: Past challenges and future hopes

Jose H. Flores-Arredondo; Gerardo García-Rivas; Guillermo Torre-Amione

doi:10.1007/s11897-010-0044-2

Immune modulation in heart failure: Past challenges and future hopes

Jose H. Flores-Arredondo, Gerardo García-Rivas, Guillermo Torre-Amione

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Immune-modulation therapy has had great success in various inflammatory diseases. Despite the promising results of preliminary studies in anti-tumor necrosis factor-α therapies, large randomized studies have lacked positive clinical outcomes in patients with heart failure. These results have led to the idea that therapies directed toward specific inflammatory mediators may not be the answer and lead us toward the development of novel anti-inflammatory strategies that may involve a broader spectrum of inflammatory mediators. Therapeutic plasma exchange has been demonstrated as a safe treatment, and preliminary outcomes led us to develop new treatment schemes.

Original language	English (US)
Pages (from-to)	28-37
Number of pages	10
Journal	Current heart failure reports
Volume	8
Issue number	1
DOIs	https://doi.org/10.1007/s11897-010-0044-2
State	Published - Mar 2011

Keywords

Cytokines
Heart failure
Immune modulation
Interleukin-1
Interleukin-6
Intravenous immunoglobulin
Neurohormonal
Therapeutic plasma exchange
Tumor necrosis factor-α

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)
Emergency Medicine

Access to Document

10.1007/s11897-010-0044-2

Cite this

@article{9ca1f2bdb92f4aaf9d1d0874a6a68aa9,

title = "Immune modulation in heart failure: Past challenges and future hopes",

abstract = "Immune-modulation therapy has had great success in various inflammatory diseases. Despite the promising results of preliminary studies in anti-tumor necrosis factor-α therapies, large randomized studies have lacked positive clinical outcomes in patients with heart failure. These results have led to the idea that therapies directed toward specific inflammatory mediators may not be the answer and lead us toward the development of novel anti-inflammatory strategies that may involve a broader spectrum of inflammatory mediators. Therapeutic plasma exchange has been demonstrated as a safe treatment, and preliminary outcomes led us to develop new treatment schemes.",

keywords = "Cytokines, Heart failure, Immune modulation, Interleukin-1, Interleukin-6, Intravenous immunoglobulin, Neurohormonal, Therapeutic plasma exchange, Tumor necrosis factor-α",

author = "Flores-Arredondo, {Jose H.} and Gerardo Garc{\'i}a-Rivas and Guillermo Torre-Amione",

year = "2011",

month = mar,

doi = "10.1007/s11897-010-0044-2",

language = "English (US)",

volume = "8",

pages = "28--37",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "1",

}

TY - JOUR

T1 - Immune modulation in heart failure

T2 - Past challenges and future hopes

AU - Flores-Arredondo, Jose H.

AU - García-Rivas, Gerardo

AU - Torre-Amione, Guillermo

PY - 2011/3

Y1 - 2011/3

N2 - Immune-modulation therapy has had great success in various inflammatory diseases. Despite the promising results of preliminary studies in anti-tumor necrosis factor-α therapies, large randomized studies have lacked positive clinical outcomes in patients with heart failure. These results have led to the idea that therapies directed toward specific inflammatory mediators may not be the answer and lead us toward the development of novel anti-inflammatory strategies that may involve a broader spectrum of inflammatory mediators. Therapeutic plasma exchange has been demonstrated as a safe treatment, and preliminary outcomes led us to develop new treatment schemes.

AB - Immune-modulation therapy has had great success in various inflammatory diseases. Despite the promising results of preliminary studies in anti-tumor necrosis factor-α therapies, large randomized studies have lacked positive clinical outcomes in patients with heart failure. These results have led to the idea that therapies directed toward specific inflammatory mediators may not be the answer and lead us toward the development of novel anti-inflammatory strategies that may involve a broader spectrum of inflammatory mediators. Therapeutic plasma exchange has been demonstrated as a safe treatment, and preliminary outcomes led us to develop new treatment schemes.

KW - Cytokines

KW - Heart failure

KW - Immune modulation

KW - Interleukin-1

KW - Interleukin-6

KW - Intravenous immunoglobulin

KW - Neurohormonal

KW - Therapeutic plasma exchange

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=79551508882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551508882&partnerID=8YFLogxK

U2 - 10.1007/s11897-010-0044-2

DO - 10.1007/s11897-010-0044-2

M3 - Article

C2 - 21221862

AN - SCOPUS:79551508882

SN - 1546-9530

VL - 8

SP - 28

EP - 37

JO - Current heart failure reports

JF - Current heart failure reports

IS - 1

ER -

Immune modulation in heart failure: Past challenges and future hopes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this